[ { "report_key": "2026:q1", "period_label": "2026 Q1", "date": "2026-04-29", "title": "Kvartalsrapport Q1 2026", "original_title": "Kvartalsrapport Q1 2026", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b6eed573445c5007fad22497e9ea6e15a&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709", "date": "2026-04-29", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf", "text_chars": 46392, "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 46392 } ] } ], "alternatives": [] }, { "report_key": "2025:annual", "period_label": "2025 Årsredovisning", "date": "2026-03-24", "title": "Årsredovisning 2025", "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2025", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bd422734e05445b3d94aa01527b8e5ec3&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a", "date": "2026-03-24", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf", "text_chars": 315393, "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 176425 }, { "number": 2, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 138966 } ] } ], "alternatives": [] }, { "report_key": "2025:q4", "period_label": "2025 Q4", "date": "2026-02-26", "title": "Kvartalsrapport Q4 2025", "original_title": "Bokslutskommuniké januari-december 2025", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b44b80c3eb35069e5d3ef27619cf43fbf&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53", "date": "2026-02-26", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf", "text_chars": 49800, "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 49800 } ] } ], "alternatives": [] }, { "report_key": "2025:q3", "period_label": "2025 Q3", "date": "2025-11-25", "title": "Kvartalsrapport Q3 2025", "original_title": "Kvartalsrapport Q3 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b2bc7bcb707477cbbca001cd7f5bbfe7f&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4", "date": "2025-11-25", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "Q3_2025_Report_SE_Final_251125.pdf", "text_chars": 50087, "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 50087 } ] } ], "alternatives": [] }, { "report_key": "2025:q2", "period_label": "2025 Q2", "date": "2025-08-21", "title": "Kvartalsrapport Q2 2025", "original_title": "Kvartalsrapport Q2 2025", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bdc02099a782352223cdc8a80791bb306&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988", "date": "2025-08-21", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf", "text_chars": 9423, "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 9423 } ] } ], "alternatives": [] }, { "report_key": "2025:q1", "period_label": "2025 Q1", "date": "2025-04-30", "title": "Kvartalsrapport Q1 2025", "original_title": "Kvartalsrapport Q1 2025", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b04407352577b944f1db775fbba6cc0a5&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf", "date": "2025-04-30", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf", "text_chars": 322374, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 177753 }, { "number": 2, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-002.html", "chars": 144619 } ] } ], "alternatives": [] }, { "report_key": "2024:annual", "period_label": "2024 Årsredovisning", "date": "2025-04-11", "title": "Årsredovisning 2024", "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b5e86dbf640e2107ef0195a10490f2570&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f", "date": "2025-04-11", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf", "text_chars": 322374, "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 177753 }, { "number": 2, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html", "chars": 144619 } ] } ], "alternatives": [] }, { "report_key": "2024:q4", "period_label": "2024 Q4", "date": "2025-02-26", "title": "Kvartalsrapport Q4 2024", "original_title": "Bokslutskommuniké januari-december 2024", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b54c8861ab69dd5eb6b82cb4c09c9ecfd&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3", "date": "2025-02-26", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf", "text_chars": 60074, "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 60074 } ] } ], "alternatives": [] }, { "report_key": "2024:q3", "period_label": "2024 Q3", "date": "2024-11-08", "title": "Kvartalsrapport Q3 2024", "original_title": "Kvartalsrapport Q3 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b3079030691d8cfcfff1aa18663986305&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07", "date": "2024-11-08", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf", "text_chars": 63859, "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 63859 } ] } ], "alternatives": [] }, { "report_key": "2024:q2", "period_label": "2024 Q2", "date": "2024-08-22", "title": "Kvartalsrapport Q2 2024", "original_title": "Kvartalsrapport Q2 2024", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bf3afba6a33edcdc6e6188bc8f6cfd633&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1", "date": "2024-08-22", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "Q2_2024_Report_SE_240822_Final.pdf", "text_chars": 11615, "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 11615 } ] } ], "alternatives": [] }, { "report_key": "2024:q1", "period_label": "2024 Q1", "date": "2024-05-03", "title": "Kvartalsrapport Q1 2024", "original_title": "Kvartalsrapport Q1 2024", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b5d81534397dc40acd5a145f1bab09c3c&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc", "date": "2024-05-03", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "Q1_2024_Report_SE_240502_Final3.pdf", "text_chars": 18247, "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 18247 } ] } ], "alternatives": [] }, { "report_key": "2023:annual", "period_label": "2023 Årsredovisning", "date": "2024-04-15", "title": "Årsredovisning 2023", "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2023", "category": "Bokslut och Verksamhetsberättelse", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bf825d303bbb3f339d86185713acda286&lang=sv&src=listed", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e", "date": "2024-04-15", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf", "text_chars": 318947, "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 176539 }, { "number": 2, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 142406 } ] } ], "alternatives": [] }, { "report_key": "2023:q4", "period_label": "2023 Q4", "date": "2024-02-22", "title": "Kvartalsrapport Q4 2023", "original_title": "Bokslutskommuniké januari-december 2023", "category": "Bokslutskommuniké", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bda8425e5dd15751763854e309cc2a802&lang=sv&src=listed", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6", "date": "2024-02-22", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf", "text_chars": 12027, "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 12027 } ] } ], "alternatives": [] }, { "report_key": "2023:q3", "period_label": "2023 Q3", "date": "2023-11-08", "title": "Kvartalsrapport Q3 2023", "original_title": "Kvartalsrapport Q3 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b4b37225e0947f3a95bc7db73dc9508a9&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696", "date": "2023-11-08", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "Q3_2023_Report_SE_231108_Final.pdf", "text_chars": 14617, "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 14617 } ] } ], "alternatives": [] }, { "report_key": "2023:q2", "period_label": "2023 Q2", "date": "2023-08-22", "title": "Kvartalsrapport Q2 2023", "original_title": "Kvartalsrapport Q2 2023", "category": "Halvårsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b29970ae3290eb0fee17334f1634fc4f4&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2", "date": "2023-08-22", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf", "text_chars": 12420, "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 12420 } ] } ], "alternatives": [] }, { "report_key": "2023:q1", "period_label": "2023 Q1", "date": "2023-04-26", "title": "Kvartalsrapport Q1 2023", "original_title": "Delårsrapport januari-mars 2023", "category": "Interimsrapport", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b8eda6e67ac908da1643016b7ac20eb8f&lang=sv&src=listed", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182", "date": "2023-04-26", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf", "text_chars": 11347, "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c", "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 11347 } ] } ], "alternatives": [] } ]